Calcium carbonate powder as a phosphate binder

D. Miller, Tim Taber, T. F. Hegeman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

With increasing recognition of problems regarding the use of aluminum hydroxide as a phosphate binder, calcium carbonate has become the medication of choice. Use of calcium has, however, frequently been associated with development of hypercalcemia. At this institution, calcium carbonate powder as a phosphate binder, examination of its efficacy, and the frequency of hypercalcemia with its use were of great interest. Calcium carbonate powder (CalCarb-HD, 2.4 gms elemental calcium/packet) (CalCarb-HD, Lafayette Pharmacal Inc., Fort Worth, TX) was used in the study. Twenty-one end-stage renal disease (ESRD) patients (17 hemodialysis and 4 chronic ambulatory peritoneal dialysis) were chosen and converted from their previous binder (primarily, calcium carbonate tablets) to calcium powder. The dosage was adjusted to keep phosphorus levels at 3.5 to 5.5 mg/dl and calcium < 11.5 mg/dl. At 2 months, the average calcium level in the 16 patients remaining in the study was 9.2 mg/dl, and the average phosphorus level was 5.2 mg/dl with an average calcium dose of 1.4 packets/day. By 7 months, the 8 patients remaining in the study had an average calcium level of 9.9 mg/dl with an average phosphorus level of 5.5 mg/dl; average calcium dose was 1.8 packets/day. Total episodes of hypercalcemia (calcium greater than 11.5 mg/dl) were two. Calcium carbonate powder appears to be an effective phosphate binder in the ESRD population. The relatively few episodes of hypercalcemia may be related to possible enhanced bioavailability of the compound secondary to its powdered form.

Original languageEnglish
Pages (from-to)322-324
Number of pages3
JournalASAIO Transactions
Volume35
Issue number3
StatePublished - Jul 1989

Fingerprint

Calcium Carbonate
Calcium carbonate
Powders
Binders
Calcium
Phosphates
Hypercalcemia
Phosphorus
Chronic Kidney Failure
Aluminum Hydroxide
Hydrated alumina
Dialysis
Peritoneal Dialysis
Biological Availability
Tablets
Renal Dialysis

ASJC Scopus subject areas

  • Biophysics

Cite this

Miller, D., Taber, T., & Hegeman, T. F. (1989). Calcium carbonate powder as a phosphate binder. ASAIO Transactions, 35(3), 322-324.

Calcium carbonate powder as a phosphate binder. / Miller, D.; Taber, Tim; Hegeman, T. F.

In: ASAIO Transactions, Vol. 35, No. 3, 07.1989, p. 322-324.

Research output: Contribution to journalArticle

Miller, D, Taber, T & Hegeman, TF 1989, 'Calcium carbonate powder as a phosphate binder', ASAIO Transactions, vol. 35, no. 3, pp. 322-324.
Miller D, Taber T, Hegeman TF. Calcium carbonate powder as a phosphate binder. ASAIO Transactions. 1989 Jul;35(3):322-324.
Miller, D. ; Taber, Tim ; Hegeman, T. F. / Calcium carbonate powder as a phosphate binder. In: ASAIO Transactions. 1989 ; Vol. 35, No. 3. pp. 322-324.
@article{7367c30f496043cc8050c18126ceb159,
title = "Calcium carbonate powder as a phosphate binder",
abstract = "With increasing recognition of problems regarding the use of aluminum hydroxide as a phosphate binder, calcium carbonate has become the medication of choice. Use of calcium has, however, frequently been associated with development of hypercalcemia. At this institution, calcium carbonate powder as a phosphate binder, examination of its efficacy, and the frequency of hypercalcemia with its use were of great interest. Calcium carbonate powder (CalCarb-HD, 2.4 gms elemental calcium/packet) (CalCarb-HD, Lafayette Pharmacal Inc., Fort Worth, TX) was used in the study. Twenty-one end-stage renal disease (ESRD) patients (17 hemodialysis and 4 chronic ambulatory peritoneal dialysis) were chosen and converted from their previous binder (primarily, calcium carbonate tablets) to calcium powder. The dosage was adjusted to keep phosphorus levels at 3.5 to 5.5 mg/dl and calcium < 11.5 mg/dl. At 2 months, the average calcium level in the 16 patients remaining in the study was 9.2 mg/dl, and the average phosphorus level was 5.2 mg/dl with an average calcium dose of 1.4 packets/day. By 7 months, the 8 patients remaining in the study had an average calcium level of 9.9 mg/dl with an average phosphorus level of 5.5 mg/dl; average calcium dose was 1.8 packets/day. Total episodes of hypercalcemia (calcium greater than 11.5 mg/dl) were two. Calcium carbonate powder appears to be an effective phosphate binder in the ESRD population. The relatively few episodes of hypercalcemia may be related to possible enhanced bioavailability of the compound secondary to its powdered form.",
author = "D. Miller and Tim Taber and Hegeman, {T. F.}",
year = "1989",
month = "7",
language = "English",
volume = "35",
pages = "322--324",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Calcium carbonate powder as a phosphate binder

AU - Miller, D.

AU - Taber, Tim

AU - Hegeman, T. F.

PY - 1989/7

Y1 - 1989/7

N2 - With increasing recognition of problems regarding the use of aluminum hydroxide as a phosphate binder, calcium carbonate has become the medication of choice. Use of calcium has, however, frequently been associated with development of hypercalcemia. At this institution, calcium carbonate powder as a phosphate binder, examination of its efficacy, and the frequency of hypercalcemia with its use were of great interest. Calcium carbonate powder (CalCarb-HD, 2.4 gms elemental calcium/packet) (CalCarb-HD, Lafayette Pharmacal Inc., Fort Worth, TX) was used in the study. Twenty-one end-stage renal disease (ESRD) patients (17 hemodialysis and 4 chronic ambulatory peritoneal dialysis) were chosen and converted from their previous binder (primarily, calcium carbonate tablets) to calcium powder. The dosage was adjusted to keep phosphorus levels at 3.5 to 5.5 mg/dl and calcium < 11.5 mg/dl. At 2 months, the average calcium level in the 16 patients remaining in the study was 9.2 mg/dl, and the average phosphorus level was 5.2 mg/dl with an average calcium dose of 1.4 packets/day. By 7 months, the 8 patients remaining in the study had an average calcium level of 9.9 mg/dl with an average phosphorus level of 5.5 mg/dl; average calcium dose was 1.8 packets/day. Total episodes of hypercalcemia (calcium greater than 11.5 mg/dl) were two. Calcium carbonate powder appears to be an effective phosphate binder in the ESRD population. The relatively few episodes of hypercalcemia may be related to possible enhanced bioavailability of the compound secondary to its powdered form.

AB - With increasing recognition of problems regarding the use of aluminum hydroxide as a phosphate binder, calcium carbonate has become the medication of choice. Use of calcium has, however, frequently been associated with development of hypercalcemia. At this institution, calcium carbonate powder as a phosphate binder, examination of its efficacy, and the frequency of hypercalcemia with its use were of great interest. Calcium carbonate powder (CalCarb-HD, 2.4 gms elemental calcium/packet) (CalCarb-HD, Lafayette Pharmacal Inc., Fort Worth, TX) was used in the study. Twenty-one end-stage renal disease (ESRD) patients (17 hemodialysis and 4 chronic ambulatory peritoneal dialysis) were chosen and converted from their previous binder (primarily, calcium carbonate tablets) to calcium powder. The dosage was adjusted to keep phosphorus levels at 3.5 to 5.5 mg/dl and calcium < 11.5 mg/dl. At 2 months, the average calcium level in the 16 patients remaining in the study was 9.2 mg/dl, and the average phosphorus level was 5.2 mg/dl with an average calcium dose of 1.4 packets/day. By 7 months, the 8 patients remaining in the study had an average calcium level of 9.9 mg/dl with an average phosphorus level of 5.5 mg/dl; average calcium dose was 1.8 packets/day. Total episodes of hypercalcemia (calcium greater than 11.5 mg/dl) were two. Calcium carbonate powder appears to be an effective phosphate binder in the ESRD population. The relatively few episodes of hypercalcemia may be related to possible enhanced bioavailability of the compound secondary to its powdered form.

UR - http://www.scopus.com/inward/record.url?scp=0024704917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024704917&partnerID=8YFLogxK

M3 - Article

C2 - 2597473

AN - SCOPUS:0024704917

VL - 35

SP - 322

EP - 324

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -